|  |
|
| Tiny Battery Tech Stock Surging on Buyback Buzz |
|
| | An immunology powerhouse lifted full-year earnings guidance on strong drug sales, a consumer giant trimmed its 2025 forecast due to tariff troubles, and a next-gen battery innovator is rallying on its bold $30 million buyback program. Read on to find out more. | |
|
| | | | | What to Watch | Earnings: | | Economic Reports: | |
|
| | | | Pharmaceuticals | Immunology and Neuroscience Drive AbbVie’s Q1 Beat Despite Aesthetics Decline | | AbbVie (NYSE: ABBV) posted strong first-quarter results for fiscal 2025, with performance surpassing expectations, prompting a boost in its full-year earnings guidance. | The company reported total net revenues of $13.34 billion, up 8.4% year-over-year on a reported basis and 9.8% operationally. | Adjusted earnings per share are at $2.46, topping forecasts, while GAAP EPS is down 6.5% to $0.72, reflecting one-time R&D charges. | Don’t miss: These dark pool alerts may reveal stocks about to move—claim them now. (ad) | The quarter was propelled by standout performance in AbbVie's immunology portfolio, which generated $6.26 billion in global revenue, a jump of over 16%. | Skyrizi and Rinvoq led the charge, delivering year-over-year growth of more than 70% and 57%, respectively. | Neuroscience revenues climbed 16.1% to $2.28 billion, driven by higher Botox Therapeutic and Vraylar sales. | However, the aesthetics segment struggled, with revenue declining nearly 12% to $1.1 billion, as Juvederm and Botox Cosmetic experienced double-digit declines. | Oncology sales also saw modest growth, while Humira revenue continued its expected decline due to biosimilar competition. | CEO Robert A. Michael highlighted the company’s momentum heading into the remainder of the year, underpinned by strong pipeline developments and strategic collaborations, including a new obesity drug deal with Gubra and the FDA approval of Emblaveo for intra-abdominal infections. | AbbVie now expects full-year 2025 adjusted EPS to range from $12.09 to $12.29, slightly higher than its previous forecast. | This guidance includes a $0.13 per share impact from early-year R&D expenses but excludes future acquisition costs and potential trade policy changes. | Shares of AbbVie are up 2.67% in premarket trading. |
|
| | Consumer Goods | Colgate-Palmolive Trims Sales Forecast for 2025 Amid Tariff Headwinds | | Colgate-Palmolive (NYSE: CL) reduced its full-year guidance for organic sales growth, citing rising concerns over ongoing U.S. tariffs and their potential impact on global economic conditions. | The company now expects organic sales to rise between 2% and 4% in 2025, compared to its previous projection of 3% to 5%. | Despite the revised outlook, the consumer goods maker beat Wall Street expectations in the first quarter. | Urgent: This rare convergence of crypto catalysts may never happen again—act now or miss out. (ad) | Adjusted earnings per share are at $0.91, above the consensus forecast of $0.86. | However, total net sales are down 3% year-over-year to $4.91 billion, while organic sales are up by 1.4%. | CEO Noel Wallace acknowledged how market uncertainty, driven largely by President Donald Trump’s recent wave of tariffs, continues to challenge the company’s long-term planning and pricing strategies. | Wallace reaffirmed confidence in Colgate’s business model, emphasizing its agility and focus on execution amid global disruption. | The updated forecast also includes a revised gross profit margin outlook. Colgate now expects margins to remain roughly flat as a percentage of net sales, scaling back its previous guidance of flat to slightly higher margins. | The company trimmed its expected earnings-per-share growth from a “low to mid-single digit” range to “low-single digits.” | Colgate joins a growing list of major U.S. firms—including Procter & Gamble (NYSE: PG), PepsiCo (NASDAQ: PEP), and American Airlines (NASDAQ: AAL)—that have cut or withdrawn financial projections due to tariff uncertainty and its downstream impact on consumer behavior and global supply chains. | Shares of Colgate-Palmolive are up 0.76% in premarket trading. |
|
| | Magnificent Seven 2.0 (Sponsored) | |  | Image source: Live Index |
| Everyone knows the Magnificent Seven—Apple, Amazon, Tesla, and the rest. But those stocks have already made their historic runs. | The real opportunity now? Spotting the next generation of market leaders before they go mainstream. | A brand-new report just revealed 7 under-the-radar companies with the potential to mirror the rise of the original Magnificent Seven. | They’re growing fast, expanding market share, and still flying below Wall Street’s radar—for now. | [Get the names and tickers before the next bull run begins.] | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) |
|
| | Insurance | Aon Tops Revenue Forecasts, But EPS Misses Despite Strong Adjusted Results | | Aon PLC (NYSE: AON) reported robust first-quarter performance, with revenue rising 16% year-over-year to $4.7 billion. | While this is above analyst projections of $4.62 billion, the company's diluted earnings per share (EPS) are at $4.43, missing the $4.85 consensus. | Aon’s shares are slipping by 2.75% in premarket trade. | However, adjusted EPS is above expectations at $5.67, slightly ahead of the $5.66 reported a year earlier. | You might like: A hidden options system has worked 97% of the time for 8 years—find out the exact phrase now. (ad) | CEO Greg Case highlighted that the company is gaining momentum as it moves into the second year of its “3x3 Plan,” with mid-single-digit organic revenue growth and continued operating discipline driving performance. | Organic revenue has risen 5%, supported by contributions from the NFP acquisition and steady demand across its insurance, reinsurance, and HR advisory services. | Despite the revenue strength, operating income has dipped marginally to $1.461 billion from $1.465 billion, while operating margin narrowed to 30.9% from 36.0%. | Adjusted operating income has grown by 12% to $1.816 billion, though adjusted margins also edged lower to 38.4%. | The effective tax rate improved to 21.4%, down from 23.2% in Q1 2024. | On the cash flow front, operating cash has dropped 55% to $140 million, and free cash flow fell 68% to $84 million. | Nevertheless, Aon has returned $397 million to shareholders via dividends and buybacks and announced a 10% hike in its quarterly dividend—its fifteenth consecutive annual increase. | Aon also reaffirmed its full-year guidance, projecting continued mid-single-digit or better organic revenue growth and strong adjusted EPS expansion, despite ongoing challenges from foreign exchange fluctuations and cost pressures. |
|
| | Movers and Shakers | | SES AI Corporation [SES] - Last Close: $0.87 | SES AI Corporation is a next-gen AI-based battery technology company. | Its stock is surging over 27% in premarket trading after SES AI announced a $30 million stock repurchase plan—an aggressive move given its recent 66% YTD decline. | My Take: SES AI’s buyback is a bold bet in the face of NYSE delisting pressure—but with zero debt and ample cash, they’ve got runway. Still, profitability and commercial traction remain key hurdles to watch. |
|
|
|
| Azitra Inc [AZTR] - Last Close: $0.31 | Azitra Inc. is a clinical-stage biopharma company. | Its stock is rising 25% in premarket trading after Azitra announced a share purchase agreement with Alumni Capital for up to $20 million in funding. | My Take: Azitra's deal with Alumni Capital gives it breathing room to pursue rare disease therapies without crushing shareholder dilution. But with limited revenue and high R&D burn, it might be best to keep this stock on your wait and watch list for now. |
|
|
|
| Ironwood Pharmaceuticals, Inc. [IRWD] - Last Close: $0.88 | Ironwood Pharmaceuticals is a biotech firm focused on gastrointestinal and rare diseases. | Despite a sharp 46% drop in Q1 net sales year-over-year due to rebate accounting and pricing pressures, the company reaffirmed its full-year sales outlook and raised adjusted EBITDA guidance from $85M to over $105M, which is causing its shares to rise in premarket trade. | My Take: Ironwood’s fundamentals remain intact despite the Q1 results. Investors are reassured by the EBITDA raise and stable demand in its flagship LINZESS product, signaling a rebound in sentiment. Keep this on your radar. |
|
|
|
| | | | | | That’s all for today. Thank you for reading. If you have any feedback, please reply to this email. | Best Regards, | — Adam Garcia
Elite Trade Club |
|
| | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
